Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03223493
Other study ID # INS-4409
Secondary ID U1111-1198-9657
Status Completed
Phase
First received
Last updated
Start date October 29, 2015
Est. completion date November 12, 2015

Study information

Verified date July 2019
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The ACTION (Awareness, Care, and Treatment In Obesity management) study aims to identify perceptions, attitudes, behaviours, and potential barriers to effective obesity care across three respondent types: 1) People with Obesity, 2) Healthcare Providers and 3) Employer Representatives in the US. Data is collected via online surveys using a cross-sectional, US-based stratified sample design.


Recruitment information / eligibility

Status Completed
Enrollment 3767
Est. completion date November 12, 2015
Est. primary completion date November 12, 2015
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- GENERAL POPULATION

- Agrees to AE reporting

- Age at least 18 years

- Lives in the US

- Current BMI at least 30 kg/sqm

- HEALTH CARE PROFESSIONALS

- Agrees to AE reporting

- Physician and board certified or NP/PA

- Facility located in the U.S. and not Vermont

- Spends at least 70% of time in direct patient care

- Seen at least 100 patients in past month

- Seen at least 10 patients in past month needing weight management

- In practice 2-35 years

- Not competitively employed

- Primary Care Providers

- Specialty is FP, IM, GP

- Less than 50% patients seen for obesity

- Obesity Specialists

- Obesity medicine or weight loss specialist or at least 50% of patients seen for obesity

- In practice 2-35 years

- EMPLOYERS

- Age at least 18 years

- Works in the US

- Director, Administrator, CHRO, VP or other title

- Responsible for making or influencing decisions about health insurance or health and wellness programs

- Company employs 500 or more full-time employees

- Believes there is a weight issue at their company

- Not competitively employed

Exclusion Criteria:

- None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No treatment given
Completion of a questionnaire

Locations

Country Name City State
United States Novo Nordisk Investigational Site Honeoye Falls New York

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

United States, 

References & Publications (3)

Jinnett K, Kyle T, Parry T, Stevenin B, Ramasamy A. Insights into the Role of Employers Supporting Obesity Management in People with Obesity: Results of the National ACTION Study. Popul Health Manag. 2018 Oct 31. doi: 10.1089/pop.2018.0133. [Epub ahead of — View Citation

Kaplan LM, Golden A, Jinnett K, Kolotkin RL, Kyle TK, Look M, Nadglowski J, O'Neil PM, Parry T, Tomaszewski KJ, Stevenin B, Lilleøre SK, Dhurandhar NV. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity (Sil — View Citation

Look M, Kolotkin RL, Dhurandhar NV, Nadglowski J, Stevenin B, Golden A. Implications of differing attitudes and experiences between providers and persons with obesity: results of the national ACTION study. Postgrad Med. 2019 Jun;131(5):357-365. doi: 10.10 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Awareness with the care and management of obesity among people with obesity Data is collected via online questionnaires using a cross-sectional, US-based stratified sample design Start of interviews day 1 until day 15
Primary Awareness with the care and management of obesity among health care providers Data is collected via online questionnaires using a cross-sectional, US-based stratified sample design Start of interviews day 1 until day 15
Primary Awareness with the care and management of obesity among employer representatives Data is collected via online questionnaires using a cross-sectional, US-based stratified sample design Start of interviews day 1 until day 15
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2